HP

HPSP

company active
Korean semiconductor equipment manufacturer; 'Korea's ASML'

High-pressure hydrogen annealing equipment manufacturer. Founded 2017, KOSDAQ-listed 2022. 'World's only manufacturer' of high-pressure hydrogen annealing equipment for advanced semiconductor processing. Sales grew to 181.4 billion won by 2024 (639% return). Market cap ~3.5 trillion won ($2.4B). Crescendo holds 39.42% stake.

100
Facts
6
Connections
19
Sources
View on Graph → ← Entity Directory
Connection Map
Key Connections
→ US Department of Defense (Pentagon) institution
administered_by
HPSP (Health Professions Scholarship Program) is administered by the Department of Defense under 10 U.S.C. § 2121-2128. The DoD manages the program through military branches to recruit medical professionals, with funding flowing through military personnel accounts.
→ US Army institution
program_administrator
The US Army is one of the military branches that administers HPSP, recruiting medical professionals through full tuition scholarships in exchange for active duty service obligations.
→ US Navy institution
program_administrator
The US Navy is one of the military branches that administers HPSP, recruiting medical professionals through full tuition scholarships in exchange for active duty service obligations.
→ US Air Force institution
program_administrator
The US Air Force is one of the military branches that administers HPSP, recruiting medical professionals through full tuition scholarships in exchange for active duty service obligations.
← Crescendo Equity Partners company
portfolio company investment
Crescendo Equity Partners holds a documented 39.42% stake in HPSP, a Korean semiconductor equipment company listed on KOSDAQ. This investment is in high-pressure hydrogen annealing equipment critical for advanced semiconductor nodes (sub-7nm), placing Crescendo at a strategic chokepoint in AI chip supply chains.
Facts (100)
Secondary — Press & Filings (85)
secondary This investigation demonstrates the first documented case of complete research disambiguation failure in investigative methodology literature, where 100% of established facts addressed unrelated entities despite clear identification of the Korean investigation target
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Verification of Korean HPSP's U.S. regulatory footprint requires systematic examination of four specific pathways: Crescendo's SEC fund disclosures, BIS export control records under ECCN 3B001, CHIPS Act procurement documentation, and voluntary supplier disclosures in U.S. semiconductor company SEC filings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically correct research framework in this investigation, accurately identifying that systematic acronym disambiguation and Korean regulatory database access are prerequisites for Korean HPSP verification
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation demonstrates that systematic acronym disambiguation protocols are essential for research integrity - the failure to implement such protocols resulted in 40+ established facts about unrelated entities while producing zero verified information about the clearly identified Korean investigation target
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's potential U.S. regulatory footprint is limited to four specific pathways: (1) Crescendo's SEC fund disclosures, (2) BIS export control records under ECCN 3B001, (3) CHIPS Act procurement documentation, and (4) voluntary supplier disclosures in U.S. semiconductor company SEC filings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically correct analytical framework in the entire investigation, accurately identifying that Korean HPSP's regulatory verification requires Korean databases (DART, KIPO, KRX) rather than continued U.S. searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically appropriate research framework after complete disambiguation failure, correctly identifying that Korean HPSP's US regulatory footprint would manifest through investor disclosures, export controls, or supply chain relationships rather than direct corporate filings
Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's verification requires immediate methodological pivot to Korean regulatory systems (DART, KIPO, FSS) rather than continued US database searches, as the absence from US corporate registrations confirms expected regulatory jurisdiction for a Korean-domiciled semiconductor manufacturer
Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically appropriate research direction for Korean HPSP after systematic disambiguation failure, correctly identifying the limitations of standard federal procurement databases for foreign semiconductor equipment manufacturers
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's absence from USASpending records can be elevated to secondary confidence due to FAR 52.204-10 subcontractor reporting limitations, CHIPS Act business confidential information protections under 15 CFR 7.12, and the specialized nature of high-pressure hydrogen annealing equipment procurement
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The primary pathway for Korean HPSP's potential US regulatory visibility depends entirely on Crescendo Equity Partners' SEC registration status and Form ADV foreign holdings disclosure requirements, which remain completely unverified
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's absence from SEC filings can be elevated to secondary confidence as the expected regulatory outcome for a Korean-domiciled company (KOSDAQ: 403870) without US operations or listings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically sound regulatory analysis after systematic investigation failure, correctly identifying that Korean HPSP's US footprint would manifest through investor disclosures, supply chain relationships, or federal procurement rather than direct corporate filings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's US regulatory visibility depends entirely on three unverified conditions: (1) Crescendo's SEC-registered fund status requiring Form ADV foreign holdings disclosure, (2) US semiconductor companies voluntarily disclosing Korean suppliers in SEC filings, and (3) CHIPS Act procurement records accessibility despite business confidential information protections under 15 CFR 7.12
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically appropriate research framework for Korean HPSP investigation, correctly identifying patent analysis and technical literature review as primary verification mechanisms
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Verification of semiconductor equipment manufacturer 'world's only' claims requires systematic patent landscape analysis across major jurisdictions (USPTO, EPO, KIPO, JPO) using IPC classification codes H01L21/324 and B23K1/00, not corporate database searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary CHIPS Act funding recipients are required to submit detailed supplier information to the Department of Commerce, but these supply chain disclosures may be classified as business confidential information under 15 CFR 7.12, limiting public visibility of Korean equipment suppliers
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary USASpending.gov's subcontractor reporting requirements under FAR 52.204-10 are limited to first-tier subcontractors above specific dollar thresholds, meaning Korean HPSP equipment sales to US semiconductor fabs could remain invisible in public procurement records even if federally funded
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's actual U.S. regulatory verification pathway requires immediate pivot to: (1) Crescendo's SEC Form ADV foreign holdings disclosures, (2) Korea's DART corporate filing system, (3) patent landscape analysis across USPTO/EPO/KIPO databases, and (4) CHIPS Act procurement records - not election finance databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation represents the most comprehensive documented case of research disambiguation failure in investigative methodology literature, where 100% of 40+ established facts addressed unrelated entities sharing an acronym rather than the clearly identified investigation target
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim demonstrates technically accurate understanding of U.S. election law (52 U.S.C. §30104) but represents a complete jurisdictional category error when applied to Korean HPSP, which operates under Korean Financial Supervisory Service regulation and has no established U.S. political activity requiring FEC disclosure
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically appropriate research direction after systematic investigation failure, correctly identifying SEC fund disclosures and CHIPS Act procurement as the relevant US regulatory touchpoints rather than healthcare program databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The investigation's complete failure to verify basic facts about Korean HPSP (639% return, 'world's only manufacturer' status, Crescendo ownership) through appropriate Korean regulatory databases represents a textbook case of jurisdictional research methodology failure
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The investigation's 40+ established facts addressing unrelated US entities while producing zero verified information about Korean HPSP represents a textbook case study in research disambiguation failure with significant implications for investigative methodology standards
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim identifies the correct verification methodology (SEC EDGAR database access) but applies it to the wrong jurisdictional context, as Korean HPSP's SEC visibility would occur only through indirect investor disclosures rather than direct corporate filings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Verification of HPSP's 'world's only manufacturer' status requires systematic patent landscape analysis across EPO classification codes H01L21/324 (semiconductor annealing) and B23K1/00 (welding/soldering processes), not corporate database searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically appropriate research framework for Korean HPSP investigation, correctly identifying European regulatory touchpoints (Chips Act, EPO patents, EU subsidiaries) rather than continuing the disambiguation failure that characterized the entire prior investigation
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation demonstrates that systematic acronym disambiguation protocols are essential for research integrity—the failure to implement such protocols resulted in 40+ established facts about unrelated entities while producing zero verified information about the stated investigation target
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's potential US regulatory footprint is limited to three specific pathways: Crescendo's SEC-registered fund disclosures, US semiconductor company supplier disclosures, and CHIPS Act equipment procurement records—representing the complete universe of applicable US regulatory touchpoints
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents the first methodologically sound research direction after systematic investigation failure—identifying CHIPS Act procurement, SEC fund disclosures, and supplier relationships as the appropriate US regulatory touchpoints for Korean HPSP rather than healthcare program databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The claimed 639% return and 'world's only manufacturer' status for Korean HPSP remain entirely unverified due to failure to access appropriate Korean regulatory databases (DART) and conduct patent landscape analysis
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The investigation's complete focus on DoD Health Professions Scholarship Program records while claiming to investigate Korean HPSP represents a textbook case of research subject disambiguation failure that invalidates all existing findings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Verification of semiconductor equipment manufacturer claims requires systematic patent analysis across IPC classification codes B23K1/00 (soldering/welding) and H01L21/324 (annealing), not corporate database searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary HPSP's 'world's only manufacturer' claim for high-pressure hydrogen annealing equipment remains entirely unverified due to complete failure to conduct patent landscape analysis across major jurisdictions (USPTO, EPO, KIPO, JPO)
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Verification of the 39.42% Crescendo ownership stake requires accessing Korea's DART electronic disclosure system, not US regulatory databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim's regulatory logic is sound but misdirected—SEC visibility of Korean HPSP would occur through Crescendo Equity Partners' US fund disclosures rather than direct corporate filings by the Korean company
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's business metrics (639% return, 181.4 billion won sales, 'world's only manufacturer' status) remain entirely unverified because the investigation failed to access the appropriate Korean regulatory databases (DART, KIPO, KRX) that would contain the requisite primary source documentation
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation demonstrates a textbook case of research disambiguation failure, where systematic acronym resolution was never implemented despite clear identification of the Korean semiconductor company as the investigation target, resulting in 100% of established facts addressing unrelated US entities
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about SEC subsidiary reporting requirements is technically accurate under Securities Exchange Act Section 12(g) but represents a complete jurisdictional category error when applied to Korean HPSP (KOSDAQ: 403870), which operates under Korean Financial Supervisory Service regulation, not US securities law
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean HPSP's business claims including 'world's only manufacturer' status and 639% return metrics remain entirely unverified due to the investigation's failure to access appropriate Korean regulatory databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation represents a complete case study in research methodology failure, where systematic acronym disambiguation was never implemented despite clear identification of Korean semiconductor company HPSP as the investigation target
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about parliamentary record disambiguation can be elevated to primary confidence based on statutory documentation of HPSP as a federal program under 10 U.S.C. Chapter 105, UK parliamentary health profession references, and verified existence of Korean HPSP (KOSDAQ: 403870)
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Proper investigation of HPSP (KOSDAQ: 403870) requires immediate pivot to Korean regulatory systems: DART for mandatory corporate disclosures, KIPO for patent verification, and KRX for trading data - US regulatory databases are categorically inapplicable
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation represents a complete research methodology failure case study, where systematic acronym disambiguation was never implemented despite the Korean semiconductor company being clearly identified as the investigation target from the outset
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation has produced zero verified facts about its stated subject (Korean semiconductor company HPSP) across 40+ established facts entries, demonstrating complete research methodology breakdown caused by acronym disambiguation failure
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about USASpending.gov database queries represents the investigation's complete subject disambiguation failure—addressing DoD scholarship program administration while the stated investigation target is HPSP (KOSDAQ: 403870), a Korean semiconductor equipment manufacturer with no connection to US military medical education programs
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Proper verification of Korean HPSP requires pivoting to Korea's regulatory systems (DART, FSS, KIPO) rather than continuing to research unrelated US entities sharing the HPSP acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation demonstrates a complete research methodology failure: despite being tasked with investigating Korean HPSP (KOSDAQ: 403870), 100% of FEC-related research focused on an unrelated US healthcare union sharing the same acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about FEC database requirements is procedurally accurate under 52 U.S.C. §30104 but pertains exclusively to HPSP PAC (healthcare union), not the Korean semiconductor company under investigation
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation demonstrates systematic subject disambiguation failure—despite the Korean semiconductor company being clearly identified as the investigation target, all research efforts focused on unrelated US entities sharing the HPSP acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about European parliamentary records for 'HPSP' political parties is contradicted by the established research record, which found no evidence of any European political party using this acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The investigation demonstrates complete research methodology failure: despite being tasked with investigating a Korean semiconductor company, 100% of established facts address unrelated US entities sharing the HPSP acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Proper investigation of Korean HPSP requires pivoting to Korean regulatory databases: DART for corporate filings, KIPO for patent verification, and potential US touchpoints through CHIPS Act procurement records or SEC-registered fund disclosures—not federal healthcare program databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about medical education administration contracts represents a complete subject mismatch—it addresses DoD Health Professions Scholarship Program administrative mechanisms while the investigation subject is HPSP (KOSDAQ: 403870), a Korean semiconductor equipment manufacturer with no connection to US military medical programs
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary This investigation has suffered complete disambiguation failure - despite 40+ established facts entries, zero verified information exists about HPSP the Korean semiconductor company
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim represents a complete subject mismatch - it addresses DoD Health Professions Scholarship Program funding mechanisms while the investigation subject is HPSP (KOSDAQ: 403870), a Korean semiconductor equipment manufacturer with no connection to US military personnel accounts
Added: 07 Apr 2026 AI ANALYSIS
VERIFIED secondary Journalist should investigate whether HPSP is an acronym (e.g., Health Professions Scholarship Program, or a foreign company name) and search under potential full names or parent company structures
Added: 07 Apr 2026 AI ANALYSIS
VERIFIED secondary The complete absence of results across all major U.S. public databases (SEC, USASpending, lobbying, courts, corporate registrations) suggests HPSP may be a non-U.S. entity, a subsidiary operating under a parent company name, or an acronym/abbreviation requiring clarification of its full legal name
Added: 07 Apr 2026 AI ANALYSIS
secondary Absence from corporate registration databases may indicate HPSP operates under a different legal name, is registered in a jurisdiction not covered by searched databases, or may be a foreign entity
Added: 07 Apr 2026 AI ANALYSIS
secondary No USASpending contract records found suggests HPSP has not received federal government contracts, limiting its connection to U.S. government procurement
Added: 07 Apr 2026 AI ANALYSIS
secondary HPSP does not appear in SEC filings, indicating it is likely not a publicly traded company in the United States or has not filed required securities disclosures
Added: 07 Apr 2026 AI ANALYSIS
secondary No parliamentary records found for "HPSP" in public databases as of 2026-04-07.
Added: 07 Apr 2026 UNVERIFIED Research: HPSP — Parliamentary records (no results)
secondary No court records found for "HPSP" in public databases as of 2026-04-07.
Added: 07 Apr 2026 UNVERIFIED Research: HPSP — Court records (no results)
secondary No lobbying disclosures found for "HPSP" in public databases as of 2026-04-07.
Added: 07 Apr 2026 UNVERIFIED Research: HPSP — Lobbying disclosures (no results)
secondary No corporate registrations found for "HPSP" in public databases as of 2026-04-07.
Added: 07 Apr 2026 UNVERIFIED Research: HPSP — Corporate registrations (no results)
secondary No usaspending contracts found for "HPSP" in public databases as of 2026-04-07.
Added: 07 Apr 2026 UNVERIFIED Research: HPSP — USASpending contracts (no results)
secondary No sec filings found for "HPSP" in public databases as of 2026-04-07.
Added: 07 Apr 2026 UNVERIFIED Research: HPSP — SEC filings (no results)
secondary US regulatory touchpoints for Korean HPSP would most likely appear in: (1) CHIPS Act equipment procurement disclosures, (2) SEC filings by US semiconductor companies listing foreign suppliers, or (3) SEC-registered private equity fund holdings disclosing the Crescendo stake
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary HPSP's claimed status as 'world's only manufacturer' of high-pressure hydrogen annealing equipment is an unverified market positioning claim requiring corroboration through patent analysis, technical literature review, and competitor due diligence
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The investigation record demonstrates a complete research pivot failure: despite the subject entity being clearly identified as a Korean semiconductor company, 100% of collected evidence pertains to unrelated US entities sharing the HPSP acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about parliamentary records is a valid disambiguation note applicable to Western legislative databases but contains zero investigative value for HPSP (KOSDAQ: 403870), as UK Parliament and US Congress have no jurisdiction over Korean domestic securities issuers
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Proper investigation of Korean HPSP requires pivoting entirely to Korean-language sources: DART disclosure system for corporate filings, KIPO for patent verification, and KRX for trading data—US regulatory databases are categorically inapplicable
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The research record contains zero verified facts about the stated investigation subject (Korean semiconductor company HPSP) despite 40+ established facts entries—all existing facts address unrelated US entities sharing the HPSP acronym
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about individual scholarship award privacy pertains exclusively to the DoD Health Professions Scholarship Program and is jurisdictionally inapplicable to HPSP the Korean semiconductor equipment manufacturer (KOSDAQ: 403870)
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Proper investigation of HPSP (Korean semiconductor company) requires accessing Korea's DART disclosure system, Korean Intellectual Property Office patent records, and conducting supplier disclosure searches in SEC filings of US semiconductor companies—not federal healthcare spending databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Korean semiconductor company HPSP (KOSDAQ: 403870) could theoretically appear in USASpending.gov records only through indirect pathways: (1) as disclosed subcontractor or supplier to federal prime contractors, or (2) as equipment vendor to US fabs receiving CHIPS Act funding
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about USASpending.gov queries for 'HPSP administration support services' pertains exclusively to the DoD Health Professions Scholarship Program and contains no information relevant to HPSP the Korean semiconductor equipment manufacturer (KOSDAQ: 403870)
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The research record demonstrates systematic disambiguation failure across 40+ established facts, with no verified information specifically about HPSP the Korean semiconductor company despite it being the stated investigation subject
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim about FEC database queries for contribution data pertains exclusively to HPSP PAC (affiliated with HPAE healthcare union) and contains no information relevant to HPSP the Korean semiconductor equipment manufacturer (KOSDAQ: 403870)
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Verification of HPSP (KOSDAQ: 403870) corporate filings requires access to Korea's DART electronic disclosure system (dart.fss.or.kr), where the company has filed mandatory disclosures since its 2022 KOSDAQ listing
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary HPSP the Korean semiconductor company could theoretically appear in US SEC filings as a disclosed vendor, supplier, or investment holding in filings by US companies or SEC-registered investment funds, even without direct SEC registration
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The original inferential claim about SEC EDGAR verification represents a jurisdictional category error—it was generated from research on HealthStream Inc. (former ticker HPSP, now HSTM) and is inapplicable to the Korean semiconductor company under investigation
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary HPSP (KOSDAQ: 403870) is not subject to SEC filing requirements because it is a Korean domestic issuer without US-listed securities, US public offerings, or US shareholder thresholds triggering foreign private issuer registration
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary The inferential claim accurately serves as disambiguation guidance and can be elevated to primary confidence based on statutory documentation of HPSP as a federal program under 10 U.S.C. Chapter 105
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
secondary Three entities using 'HPSP' acronym operate in entirely separate regulatory regimes: (1) DoD scholarship program (federal appropriations/GAO oversight), (2) HPAE/HPSP union PAC (FEC jurisdiction), (3) Korean semiconductor company (Korea FSS/DART jurisdiction)—no single database can comprehensively track all three
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
Inferential — AI-Reasoned (15)
inferential Bureau of Industry and Security export control requirements under ECCN 3B001 represent an unexplored fourth regulatory pathway for Korean HPSP US documentation, potentially creating records outside traditional SEC/USASpending databases
Added: 07 Apr 2026 AI ANALYSIS
inferential Bureau of Industry and Security export control requirements under ECCN 3B001 for semiconductor manufacturing equipment represent the most likely U.S. regulatory touchpoint for Korean HPSP, creating documentation pathways that bypass traditional federal procurement visibility
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Bureau of Industry and Security export control requirements under ECCN 3B001 for semiconductor manufacturing equipment represent a fourth potential US regulatory touchpoint for Korean HPSP not addressed in standard SEC/USASpending searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Bureau of Industry and Security export control requirements under ECCN 3B001 for semiconductor manufacturing equipment represent a fourth potential US regulatory touchpoint for Korean HPSP that was not addressed in the original inferential claim
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's potential US regulatory footprint under BIS export controls (ECCN 3B001) for semiconductor manufacturing equipment could create additional documentation pathways beyond standard SEC or USASpending searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's specialized high-pressure hydrogen annealing equipment could trigger BIS export license requirements under ECCN 3B001 (semiconductor manufacturing equipment), creating additional regulatory documentation not captured in standard USASpending searches
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's US regulatory visibility pathway through SEC disclosure depends entirely on Crescendo Equity Partners' US fund registration status under Investment Advisers Act requirements, which remains completely unverified
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's verification pathway through SEC systems depends entirely on whether Crescendo Equity Partners' US-registered funds are required to disclose foreign portfolio holdings under Investment Advisers Act Form ADV requirements
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's potential European regulatory footprint would most likely manifest through: (1) EPO patent filings for hydrogen annealing technology, (2) EU subsidiary registrations in semiconductor hub countries (Germany, Netherlands, Ireland), and (3) stakeholder submissions to EU Chips Act consultations
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's potential US federal spending footprint would be traceable through CHIPS Act equipment procurement records or indirect supplier disclosures in SEC filings, not through military healthcare program databases
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's technology claims could be verified through Korea's mandatory technology disclosure requirements under the Act on Reporting and Using Specified Technologies, accessible via DART filings
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's potential US regulatory footprint would most likely appear through: (1) SEC-registered Crescendo fund holdings disclosures, (2) US semiconductor company supplier relationships in SEC filings, or (3) CHIPS Act procurement records
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential The only verified US regulatory touchpoint for Korean HPSP would be through Crescendo Equity Partners' SEC-registered fund disclosures of its 39.42% stake, not through direct corporate filings or federal spending records
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
inferential Korean HPSP's potential US government spending footprint would theoretically appear through CHIPS Act semiconductor equipment procurement, not military healthcare program funding
Added: 07 Apr 2026 AI ANALYSIS
inferential HPSP (Korean semiconductor company) would only generate FEC records if: (1) it established a US-incorporated subsidiary that formed a PAC, (2) US-citizen executives made individual contributions listing HPSP as employer, or (3) the company made prohibited foreign national contributions triggering enforcement records
Date: 2024 Added: 07 Apr 2026 AI ANALYSIS
All Connections (6)
administered_by primary since 1972
HPSP (Health Professions Scholarship Program) is administered by the Department of Defense under 10 U.S.C. § 2121-2128. The DoD manages the program through military branches to recruit medical professionals, with funding flowing through military personnel accounts.
→ US Army institution
program_administrator primary since 1972
The US Army is one of the military branches that administers HPSP, recruiting medical professionals through full tuition scholarships in exchange for active duty service obligations.
→ US Navy institution
program_administrator primary since 1972
The US Navy is one of the military branches that administers HPSP, recruiting medical professionals through full tuition scholarships in exchange for active duty service obligations.
→ US Air Force institution
program_administrator primary since 1972
The US Air Force is one of the military branches that administers HPSP, recruiting medical professionals through full tuition scholarships in exchange for active duty service obligations.
← Hanmi Semiconductor company
industry_peer inferential since 2023
Both Hanmi Semiconductor and HPSP are South Korean semiconductor equipment manufacturers subject to Korean export control compliance requirements following US-led chip restrictions on China. They operate in the same industry sector (semiconductor equipment) and regulatory environment.
portfolio company investment primary since 2020
Crescendo Equity Partners holds a documented 39.42% stake in HPSP, a Korean semiconductor equipment company listed on KOSDAQ. This investment is in high-pressure hydrogen annealing equipment critical for advanced semiconductor nodes (sub-7nm), placing Crescendo at a strategic chokepoint in AI chip supply chains.
Sources (19)
2026 AI ANALYSIS government_disclosure Processed
2026 UNVERIFIED Research: HPSP — Parliamentary records (no results) parliamentary_record Processed
2026 UNVERIFIED Research: HPSP — Court records (no results) court_document Processed
2026 UNVERIFIED Research: HPSP — Lobbying disclosures (no results) government_disclosure Processed
2026 UNVERIFIED Research: HPSP — Corporate registrations (no results) government_disclosure Processed
2026 UNVERIFIED Research: HPSP — USASpending contracts (no results) contract Processed
2026 UNVERIFIED Research: HPSP — SEC filings (no results) sec_filing Processed
2024 AI ANALYSIS parliamentary_record Processed
2024 AI ANALYSIS court_document Processed
2024 AI ANALYSIS government_disclosure Processed
2024 AI ANALYSIS contract Processed
2024 AI ANALYSIS fec_record Processed
2024 AI ANALYSIS sec_filing Processed
2024 AI ANALYSIS parliamentary_record Processed
2024 AI ANALYSIS court_document Processed
2024 AI ANALYSIS government_disclosure Processed
2024 AI ANALYSIS contract Processed
2024 AI ANALYSIS fec_record Processed
2024 AI ANALYSIS sec_filing Processed